形狀
powder
存貨情形
not available in USA
標籤範圍
0.60-0.95 substitution
損耗
≤15% loss on drying, 110 °C
顏色
light yellow
pH值
6.5-8.0 (10 mg/mL in H2O)
黏度
300-1000 mPa.s, 2 % in H2O(25 °C) (dry substance)
mp
> 300.05 °C ((> 572.09 °F ))
InChI
1S/C6H12O6.C2H4O2.Na/c7-1-3(9)5(11)6(12)4(10)2-8;1-2(3)4;/h1,3-6,8-12H,2H2;1H3,(H,3,4);
InChI 密鑰
DPXJVFZANSGRMM-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
R Macarrón et al.
The Biochemical journal, 289 ( Pt 3), 867-873 (1993-02-01)
Endoglucanase III (EG III) was purified to homogeneity from the culture medium of Trichoderma reesei QM 9414. It has a molecular mass of 48 kDa, and an isoelectric point of 5.1. Maximal activity was observed between pH4 and 5. Celloligosaccharides
Babak Ghanbarzadeh et al.
International journal of biological macromolecules, 48(1), 44-49 (2010-10-06)
Glycerol and oleic acid (OA) were incorporated into carboxymethyl cellulose (CMC) films by an emulsification method. Films containing different amounts of glycerol and OA were examined for mechanical properties, water vapor permeability (WVP), and moisture uptake, optical and thermal properties.
Lihua Cheng et al.
PloS one, 6(9), e25433-e25433 (2011-10-04)
Cisplatin is a potent anticancer drug, but its clinical application has been limited due to its undesirable physicochemical characteristics and severe side effects. Better drug formulations for cisplatin are highly desired. Herein, we have developed a nanoparticle formulation for cisplatin
Georg Geisberger et al.
Small (Weinheim an der Bergstrasse, Germany), 7(19), 2808-2814 (2011-09-29)
Polyoxometalate/carboxymethyl chitosan nanocomposites with an average diameter of 130 nm are synthesized and labeled with fluorescein isothiocyanate (FITC) for a combined drug-carrier and cellular-monitoring approach. [Eu(β(2) -SiW(11) O(39) )(2) ](13-) /CMC nanospheres as a representative example do not display cytotoxicity
Gunnar M Buyse et al.
European heart journal, 30(1), 116-124 (2008-09-12)
Duchenne muscular dystrophy (DMD) is a severe and still incurable disease, with heart failure as a leading cause of death. The identification of a disease-modifying therapy may require early-initiated and long-term administration, but such type of therapeutic trial is not
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门